Baird flies in the face of the Affymax (AFFY -8.1%) bloodbath, raising its price target to $17...

|By:, SA News Editor

Baird flies in the face of the Affymax (AFFY -8.1%) bloodbath, raising its price target to $17 from $15 following the FDA's approval of its anemia drug Omontys. The firm says recent weakness was primarily due to pricing concerns but they consider the weakness a buying opportunity. Shares are currently rated Outperform.